No abstract

Synchronization of oestrus has been used to increase reproductive effi ciency in most animals, including ewes. The aim of the present study was to compare the effect of the length of a progestagen treatment (12 d vs. 6 d) on synchronization effi ciency (oestrus response, time to onset of oestrus and duration of oestrus) and fertility rate using fl uorogestone acetate (FGA) progestagen sponge treatment with pregnant mare serum gonadotropin (PMSG) administration applied at different times of sponge removal. Ewes (n = 68) were divided into two groups; long term (LT, n = 33) and short term (ST, n = 35) groups treated with FGA progestagen sponges. At the end of intravaginal sponge treatment period the animals of each group were divided into the 3 subgroups in relation to time of PMSG (300 IU) treatment. PMSG treatment was applied 24 h before sponge removal, at sponge removal and 24 h after sponge removal for LT1 and ST1, LT2 and ST2, and LT3 and ST3, respectively. Each ewe was inseminated intra-cervically twice with skim cow milk-diluted semen (1000 × 10 6 motile cells/ml) 40 h and 60 h after sponge removal. Non-return rates (NRR-30) were monitored from 12 day after sponge removal to 30 day with the aid of teaser rams. Onsets of oestrus response and oestrus cessation were signifi cantly different (P < 0.05) between the ST and LT treatment groups. Synchronization of oestrus was tighter in LT than ST group. Except for oestrus cessation, other indicators studied were not different in the ST subgroups. In the ST subgroups the oestrus cessation of the ST1 (88.7 ± 15.4 h) was the shortest and differed from ST3 (120.0 ± 14.2 h) (P < 0.05). No statistical difference was observed among all studied indicators for LT groups according to application time of PMSG (P > 0.05). The NRR-30 and lambing rate of the ST and LT after timed AI were 35.7% and 31.0% and 32.1% and 28.6%, respectively (P > 0.05).

We conclude that among type 1 DM patients with similar level of glycemia, iron deficiency anemia is associated with higher concentrations of HbA1c. In addition, iron replacement therapy leads to a drop in HbA1c in both diabetic and non-diabetic patients. The iron status of the patient must be considered during the interpretation of HbA1c concentrations in type 1 DM.

Autoxidation of globin chains and iron overload are the suggested mechanisms for the increased oxidative stress in beta-thalassemia. The aim of this study was to evaluate the extend of lipid peroxidation and antioxidant status of patients with beta-thalassemia and iron deficiency anemia (IDA) and compare the results with healthy subjects. Oxidant and antioxidant status of the children with beta-thalassemia major (n = 22) and iron deficiency anemia (n = 19) were studied. Healthy controls (n = 14) were age and sex matched. Fresh anticoagulated venous blood samples were obtained from all children. Conjugated diene (CD) and thiobarbituric acid-reactive (TBARS) substances were analyzed to indicate the oxidative parameters, whereas the erythrocyte superoxide dismutase (SOD) and glutathione peroxidase (GPx) were measured to show the antioxidant status of the children. Plasma TBARS and CD concentrations were elevated in beta-thalassemia compared to IDA. When compared to the controls, elevation in TBARS was significant. In the iron-deficiency group both TBARS and CD levels were decreased compared to the controls. SOD and GPx activities were increased in the beta-thalassemia group. SOD in beta-thalassemia was higher than both IDA and the controls and GPx activity was higher than the IDA group. In vivo lipid peroxidation was increased in children with beta-thalassemia major. This leads to a compensatory increase in antioxidant enzymes, whereas IDA does not lead to lipid peroxidation with a normal antioxidant enzyme activity.

Pregnancy complicated with ITP generally has a good outcome. Although ITP in pregnancy carries a low risk, careful observation is required for the newborn of gravidas with ITP even when the infant has no bleeding complications at delivery, and infants may require treatment for thrombocytopenia.